AMSTERDAM, April 11, 2016 /PRNewswire/ -- At the 26th
European Congress of Clinical Microbiology and Infectious Diseases
(ECCMID), Bruker (Nasdaq: BRKR) introduces enhancements to the
MALDI Biotyper (MBT) routine microbial identification
workflow, and high-value expansions of the MBT assay menu to strain
subtyping and to antimicrobial resistance testing for clinical and
microbiology research:
1. MBT Biotargets 96 Further
Improve Microbiology Laboratory Efficiency and Quality with
Individually Bar-coded, Easy-to-Use and Time-saving Disposable
MALDI Sample Targets
The disposable MBT Biotargets 96 further improve
laboratory efficiency for the MALDI Biotyper
workflow. They have 96 sample spots and can be disposed of after
all spots have been utilized. The novel MBT Biotargets
96 use proprietary AnchorChip™
technology for exact sample positioning and maximum sensitivity.
The targets are individually bar-coded, providing sample
traceability for each MALDI Biotyper run, and their
unique material offers optimal flatness and product integrity. The
MBT Biotargets 96 are now available for European
clinical customers, following IVD directive EC/98/79.
2. Rapid, New MBT Subtyping Module for Research
Use Only (RUO)
The MBT Subtyping Module enables fast detection of
selected antibiotic-resistant strains in Bacteroides
fragilis and Staphylococcus aureus isolates.
Identification and resistance detection is performed in a single
automated analysis, providing species identification followed by
selected resistance information. For B. fragilis, as the
most prevalent species of the Bacteroides genus, the
MBT Subtyping Module automatically detects
carbapenemase producing strains that carry the cfiA gene.
For S. aureus the MBT Subtyping Module
detects strains carrying the mecA cassette expressing the
PSM protein. For this resistance mechanism, the new test can
differentiate MRSA (methicillin-resistant Staphylococcus
aureus) from MSSA (methicillin-sensitive Staphylococcus
aureus) within minutes.
3. Rapid, New MBT Selected Test of Antibiotic
Resistance (STAR) for Beta-lactamase (BL)
The new MBT STAR-BL assay supports the generic
detection of Gram-negative carbapenemase producers, using a
patented, functional beta-lactamase test for selected antibiotics.
The MBT STAR-BL software (RUO) monitors mass
shifts introduced by enzymatic degradation of betalactam
antibiotics, such as penicillins, 3rd- generation
cephalosporins and carbapenems. The MBT STAR-BL
test consists of a software module for easy data analysis and the
MBT STAR-BL IMI kit, which is currently in
performance evaluation studies. During the evaluation, this kit is
for investigational-use-only (IUO), and available for participating
collaboration partners.
Professor Jens Jorgen Christensen
at the Department of Clinical Microbiology at Slagelse Hospital in
Denmark stated: "Carbapenemase
producing enterobacteria strains are on the rise globally. Rapid
recognition in risk situations is desirable for optimal antibiotic
treatment of patients. The MBT STAR-BL IMI
approach will be helpful for that purpose, as increased resistance
can be detected in less than three hours."
Philip Perry, the Business
Development Manager for Consumables at Bruker Daltonics, added:
"Bruker is committed to the continuous expansion of our MALDI
Biotyper platform, e.g. with enhancements of our reference
libraries, increased customer convenience and expansion
of the MALDI Biotyper assay menu, in order to further increase
workflow ease-of-use and efficiency, and now also for rapid testing
of selected antibiotic resistance mechanisms in clinical
research."
About the Bruker MALDI Biotyper (MBT) Platform
The MALDI Biotyper family of systems enables molecular
identification of microorganisms like bacteria, yeasts and fungi.
Classification and identification of microorganisms is achieved
reliably and quickly using proteomic fingerprinting by
high-throughput MALDI-TOF mass spectrometry. The MALDI
Biotyper uses a molecular approach based on specific proteomic
fingerprints from bacterial strains. Many published studies
have highlighted the greater accuracy and lower cost offered, as
well as typically much faster time-to-result (TTR).
Applications of various MALDI Biotyper solutions include
clinical routine microbial identification, environmental and
pharmaceutical analysis, taxonomical research, food and consumer
product safety and quality control, as well as marine microbiology.
In many European and international laboratories the MALDI
Biotyper has replaced classical biochemical testing for
bacterial identification in the past few years due to the accuracy,
speed, extensive species coverage, ease of use and cost
effectiveness of the system. Traditional biochemical
techniques detect different metabolic properties of microorganisms,
can take many hours or even days for completion, and they often
lack specificity.
The robust MALDI Biotyper requires minimal sample
preparation and offers low consumables cost. The products of
the MALDI Biotyper family are available in a
research-use-only (RUO) version, as the U.S. FDA-cleared MALDI
Biotyper CA System, or in an IVD-CE version according to EU
directive EC/98/79. The MALDI Biotyper also has
medical device registrations in numerous other countries. RUO
versions of the MALDI Biotyper allow selected, high-value
antimicrobial resistance tests.
About Bruker Corporation (NASDAQ: BRKR)
For more than
50 years, Bruker has enabled scientists to make breakthrough
discoveries and develop new applications that improve the quality
of human life. Bruker's high-performance scientific research
instruments and high-value analytical solutions enable scientists
to explore life and materials at molecular, cellular and
microscopic levels.
In close cooperation with our customers, Bruker is enabling
innovation, productivity and customer success in life science
molecular research, in applied and pharma applications, in
microscopy, nano-analysis and industrial applications, as well as
in cell biology, preclinical imaging, clinical research,
microbiology and molecular diagnostics. For more information,
please visit www.bruker.com.
Photo - http://photos.prnewswire.com/prnh/20160407/353145
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bruker-introduces-important-maldi-biotyper-enhancements-at-eccmid-2016-new-disposable-mbt-biotargets-96-mbt-subtyping-and-carbapenem-resistance-tests-300248183.html
SOURCE Bruker Corporation